Hong M Moulton

Summary

Publications

  1. doi request reprint Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy
    Hong M Moulton
    AVI BioPharma, Corvallis, Oregon 97333, USA
    Ann N Y Acad Sci 1175:55-60. 2009
  2. ncbi request reprint Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate
    Adams Amantana
    AVI BioPharma, Inc, Corvallis, Oregon, USA
    Bioconjug Chem 18:1325-31. 2007
  3. pmc Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity
    Rebecca P Wu
    AVI BioPharma, Inc, Corvallis, OR 97333, USA
    Nucleic Acids Res 35:5182-91. 2007
  4. ncbi request reprint Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells
    Derek S Youngblood
    AVI BioPharma, Incorporated, 4575 SW Research Way, Corvallis, Oregon 97333, USA
    Bioconjug Chem 18:50-60. 2007
  5. doi request reprint Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy
    Hong M Moulton
    College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
    Biochim Biophys Acta 1798:2296-303. 2010
  6. doi request reprint Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers
    Hong M Moulton
    Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA
    Methods Mol Biol 867:407-14. 2012
  7. ncbi request reprint In vivo delivery of morpholino oligos by cell-penetrating peptides
    Hong M Moulton
    Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
    Curr Pharm Des 19:2963-9. 2013
  8. ncbi request reprint Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity
    Michelle H Nelson
    AVI BioPharma, Inc, Corvallis, Oregon 97333, USA
    Bioconjug Chem 16:959-66. 2005

Collaborators

Detail Information

Publications8

  1. doi request reprint Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy
    Hong M Moulton
    AVI BioPharma, Corvallis, Oregon 97333, USA
    Ann N Y Acad Sci 1175:55-60. 2009
    ..No toxicity or immunogenicity was detected. Our studies demonstrated that muscle functions can be restored with a low dose of PPMO, making it a promising therapeutic for DMD...
  2. ncbi request reprint Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate
    Adams Amantana
    AVI BioPharma, Inc, Corvallis, Oregon, USA
    Bioconjug Chem 18:1325-31. 2007
    ..In this study, we investigated the pharmacokinetics, tissue distribution, stability, and safety profile of an anti-c-myc PMO conjugated to the CPP, (RXR)4 (X = 6-aminohexanoic acid) in rats...
  3. pmc Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity
    Rebecca P Wu
    AVI BioPharma, Inc, Corvallis, OR 97333, USA
    Nucleic Acids Res 35:5182-91. 2007
    ..Toxicity of X/B-containing conjugates was affected by the number of Xs, treatment time and concentration. More active, stable and less toxic CPPs can be designed by optimizing the position and number of R, D-R, X and B residues...
  4. ncbi request reprint Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells
    Derek S Youngblood
    AVI BioPharma, Incorporated, 4575 SW Research Way, Corvallis, Oregon 97333, USA
    Bioconjug Chem 18:50-60. 2007
    ..Last, the endosomal/lysosomal trapping limits the effectiveness of a CPP-PMO conjugate, and the stability of the CPP is one of the factors affecting the ability of the conjugate to escape the endosomes/lysosomes...
  5. doi request reprint Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy
    Hong M Moulton
    College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
    Biochim Biophys Acta 1798:2296-303. 2010
    ..The toxicity of PPMOs will require caution when moving into the clinic. The first PPMO-based DMD drug is currently in preclinical development for DMD patients who can benefit from skipping exon 50...
  6. doi request reprint Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers
    Hong M Moulton
    Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA
    Methods Mol Biol 867:407-14. 2012
    ..In addition, the conjugates enter cardiomyocytes in useful quantities and improve heart functions. Here, an experimental protocol for making Tat peptide-Morpholino conjugate is described...
  7. ncbi request reprint In vivo delivery of morpholino oligos by cell-penetrating peptides
    Hong M Moulton
    Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
    Curr Pharm Des 19:2963-9. 2013
    ..PPMOs are powerful research tools for studying gene function in animals and their properties are being improved as potential human therapeutic agents...
  8. ncbi request reprint Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity
    Michelle H Nelson
    AVI BioPharma, Inc, Corvallis, Oregon 97333, USA
    Bioconjug Chem 16:959-66. 2005
    ..Additionally, it is shown that the enzymatic stability of an L- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound...